HOME >> MEDICINE >> NEWS
Initial chemotherapy treatment reduces relapses in MS patients

DENVER, CO Mitoxantrone, a chemical routinely used to fight breast cancer, leukemia and malignant lymphoma, has found a new disease to battle: Multiple Sclerosis. Used in an initial intensive course of chemotherapy (induction therapy), mitoxantrone dramatically decreases disease activity in MS patients for at least four years, according to a study presented at the Annual Meeting of the American Academy of Neurology.

Induction therapy, frequently used against cancers, is designed to wipe out abnormal cells and allow for the regrowth of normal cells. Mitoxantrone for the treatment of MS has recently been approved by the U.S. Food and Drug Administration. It has been used to treat MS in France for more than a decade. Researchers from CHU Pontchaillou of Rennes, France, have demonstrated that mitoxantrone induction therapy for relapsing-remitting MS patients has produced dramatic results in disease activity.

Over the past ten years, 100 worsening relapsing-remitting MS patients were given initial mitoxantrone induction therapy for six months, with mitoxantrone combined with methylprednisolone administered intravenously on a monthly schedule. The annual relapse rate decreased significantly from 3.20 during the 12 months preceding mitoxantrone onset to 0.30 during the first year following induction onset, corresponding to a reduction of nearly 90 percent that was maintained for more than five years. The percentage of relapse-free patients was 76 percent at one year of follow-up, and was maintained at 64 percent, 45 percent, and 43 percent at years two, three and four, respectively, with a median time to the first relapse of 2.8 years.

The clinical benefit and reduction of disease activity supports our belief that mitoxantrone, as administered in this study, may be an effective induction treatment before initiating other long-term disease modifying therapies for worsening relapsing-remitting MS patients, commented study author Emmanuelle Le Pa
'"/>

Contact: Cheryl Alementi
calementi@aan.com
651-695-2737
American Academy of Neurology
17-Apr-2002


Page: 1 2

Related medicine news :

1. Initial findings of first comprehensive study into ageing process published
2. Initial Avon/NCI breast cancer research grants awarded in Progress for Patients awards program
3. Initially recommended drug dosages often too high, study finds
4. Initial clinical study shows safety and bioactivity of cancer vaccine
5. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
6. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
7. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
8. Older women can benefit from chemotherapy to treat breast cancer
9. Resistance to chemotherapy
10. New treatment rivals chemotherapy for lymphoma, U-M study finds
11. Adding radiation therapy to chemotherapy improves survival in patients with high-risk breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/13/2017)... Boulder, CO (PRWEB) , ... January 13, 2017 , ... ... Congress, a growing alliance of deans of colleges and schools of education across the ... public schools. , In a Declaration of Principles released today, 175 deans sounded the ...
(Date:1/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a new ... way to peace, health and eternal joy. Yisrayl says he has been accused of being ... that false accusations and persecution are nothing new in his world and says it has ...
(Date:1/13/2017)... , ... January 13, 2017 , ... One way to ... nationals can qualify if they can show their work is in the national interest. ... self-petition rather than having to be sponsored by an employer; and 2) the submission ...
(Date:1/13/2017)... ... 13, 2017 , ... U.S. News & World Report highly ... its 2017 Best Online Graduate Nursing Programs list released Jan. 10. The School ... graduate degree programs include a family nurse practitioner doctor of nursing practice (DNP), ...
(Date:1/13/2017)... ... 2017 , ... PrideStaff, a national, franchised staffing organization ... franchise by Entrepreneur. , The 38th annual Franchise 500® ranking was determined using ... success. All entrants were judged by financial strength and stability, growth rate and ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... Jan 13, 2017 Research and Markets has ... and Analysis" report to their offering. ... Cystic fibrosis (CF) is a progressive ... faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. ... epithelial cells, and result in the buildup of a thick and ...
(Date:1/13/2017)... -- ... Research and Markets has announced the addition of the ... offering. The disease is divided into two categories ... melanoma, which can be treated with surgery, and advanced melanoma, which ... therapy aiming to prevent disease re-occurrence, and advanced therapies aiming to ...
(Date:1/12/2017)... Imaging, Inc., leading designer and manufacturer of the innovative ... proud to announce FDA 510(k) clearance of the G-Arm ... of the G-Arm with major improvements including axial tilt ... be launching this sooner than our original intended date," ... Marketing at Whale. "We feel that getting the B6 ...
Breaking Medicine Technology:
Cached News: